Administration précoce de témozolomide après chirurgie chez des patients ayant un glioblastome de mauvais pronostic : étude de faisabilité

Chaskis, Elly; Luce, Sylvie; Goldman, Serge; Sadeghi, Niloufar; Mélot, Christian; Witte, Olivier De; Devriendt, Daniel; Lefranc, Florence

doi:10.1016/j.bulcan.2018.05.006

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, a small pilot feasibility study showed that a single additional cycle of 5 days of 200 mg/m 2 TMZ given in the 4-week interval from surgery to standard chemoradiation was safe, feasible and associated with 71% overall survival rate at 18 months. 27 Conversely the clinical efficacy of TMZ administered prior to surgery, 28 or prolonged TMZ administered prior to and delaying chemoradiation 29 has not demonstrated efficacy. However, there have been no randomised trials demonstrating the efficacy of neoadjuvant chemotherapy compared with the current standard of care, therefore, this experimental arm of MAGMA seeks to answer this question.…”

Section: Introductionmentioning

confidence: 99%

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

et al. 2022

View full text Add to dashboard Cite

IntroductionGlioblastoma (GBM) is the most common malignant primary central nervous system cancer in adults. The objective of the Multi-Arm GlioblastoMa Australasia (MAGMA) trial is to test hypotheses in real world setting to improve survival of people with GBM. Initial experimental arms are evaluating the effectiveness of interventions in newly diagnosed GBM (ndGBM). This study will compare maximal surgical resection followed by chemoradiotherapy plus adjuvant chemotherapy for 6 months with the addition of (1) ‘neoadjuvant’ chemotherapy beginning as soon as possible after surgery and/or (2) adjuvant chemotherapy continued until progression within the same study platform.Methods and analysisMAGMA will establish a platform for open-label, multiarm, multicentre randomised controlled testing of treatments for GBM. The study began recruiting in September 2020 and recruitment to the initial two interventions in MAGMA is expected to continue until September 2023.Adults aged ≥18 years with ndGBM will be given the option of undergoing randomisation to each study intervention separately, thereby giving rise to a partial factorial design, with two separate randomisation time points, one for neoadjuvant therapy and one for extended therapy. Patients will have the option of being randomised at each time point or continuing on with standard treatment.The primary outcome for the study is overall survival from the date of initial surgery until death from any cause. Secondary outcomes include progression-free survival, time to first non-temozolomide treatment, overall survival from each treatment randomisation, clinically significant toxicity as measured by grade 3 or 4 adverse events and health-related quality-of-life measures. Tertiary outcomes are predictive/prognostic biomarkers and health utilities and incremental cost-effectiveness ratio.The primary analysis of overall survival will be performed separately for each study intervention according to the intention to treat principle on all patients randomised to each study intervention.Ethics and disseminationThe study (Protocol version 2.0 dated 23 November 2020) was approved by a lead Human Research Ethics Committee (Sydney Local Health District: 2019/ETH13297). The study will be conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice.Trial registration numberACTRN12620000048987.

show abstract

Section: Introductionmentioning

confidence: 99%

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite standard treatments consisting of surgery, postoperative radiotherapy, and chemotherapy with temozolomide. Patient survival remains poor, which is mainly attributed to tumor inherent radio-and chemoresistance (14,15).…”

mentioning

confidence: 99%

Cirsium Oleraceum L. Scop. Inhibits Cell Viability and Decreases Secretion of Matrix Metalloproteinases (Mmp2 and Mmp9) in Glioblastoma Cell Line

Naliwajko¹,

Markiewicz‐Żukowska²,

Moskwa³

et al. 2018

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

The aim of this study was to evaluate the activity of Cirsium oleraceum L. Scop. methanol extract (CoM) on likely glioblastoma (U87MG) and normal human astroglia (SVGp12) cell lines. CoM in concentrations 25; 50; 100; 250 and 500 µg/mL inducting significant dose-and time-dependent reductions of U87MG, as well as SVGp12 cells viability, in particular after 72 h of incubation. Activation of caspase-3 in U87MG cells suggests the pro-apoptotic activity of CoM. Moreover, CoM decreased secretion of matrix metalloproteinases (MMP2 and MMP9) and moderately decreased migration of U87MG cells in scratch test. These results suggest that Cirsium oleraceum L. Scop. methanol extract has anti-glioma effect in vitro through activation of caspase-3 and inhibition of metalloproteinase-2 and -9 in U87MG cells. Despite this, cytotoxic effect of CoM in normal human astroglia cells may limit its potential application in the adjuvant therapy of glioblastoma.

show abstract

Nose-to-Brain Targeting via Nanoemulsion: Significance and Evidence

Misra

Pathak

2023

Colloids and Interfaces

View full text Add to dashboard Cite

Background: Non-invasive and patient-friendly nose-to-brain pathway is the best-suited route for brain delivery of therapeutics as it bypasses the blood–brain barrier. The intranasal pathway (olfactory and trigeminal nerves) allows the entry of various bioactive agents, delivers a wide array of hydrophilic and hydrophobic drugs, and circumvents the hepatic first-pass effect, thus targeting neurological diseases in both humans and animals. The olfactory and trigeminal nerves make a bridge between the highly vascularised nasal cavity and brain tissues for the permeation and distribution, thus presenting a direct pathway for the entry of therapeutics into the brain. Materials: This review portrays insight into recent research reports (spanning the last five years) on the nanoemulsions developed for nose-to-brain delivery of actives for the management of a myriad of neurological disorders, namely, Parkinson’s disease, Alzheimer’s, epilepsy, depression, schizophrenia, cerebral ischemia and brain tumours. The information and data are collected and compiled from more than one hundred Scopus- and PubMed-indexed articles. Conclusions: The olfactory and trigeminal pathways facilitate better biodistribution and bypass BBB issues and, thus, pose as a possible alternative route for the delivery of hydrophobic, poor absorption and enzyme degradative therapeutics. Exploring these virtues, intranasal nanoemulsions have proven to be active, non-invasiveand safe brain-targeting cargos for the alleviation of the brain and other neurodegenerative disorders.

show abstract

Administration précoce de témozolomide après chirurgie chez des patients ayant un glioblastome de mauvais pronostic : étude de faisabilité

Cited by 3 publications

References 21 publications

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma

Cirsium Oleraceum L. Scop. Inhibits Cell Viability and Decreases Secretion of Matrix Metalloproteinases (Mmp2 and Mmp9) in Glioblastoma Cell Line

Nose-to-Brain Targeting via Nanoemulsion: Significance and Evidence

Contact Info

Product

Resources

About